What is the appropriate treatment for a healthy 16-year-old with recurrent multi‑site tinea (ringworm)?

Treatment for Recurrent Multi-Site Tinea in a 16-Year-Old

For a 16-year-old with recurrent ringworm on multiple body sites, oral systemic antifungal therapy is required—topical treatment alone is insufficient for recurrent or extensive disease. 1, 2

Immediate Management Approach

1. Confirm the Diagnosis

• Obtain fungal culture before starting treatment to identify the specific dermatophyte species, as this directly determines optimal drug selection 3, 2
• KOH preparation from active border of lesions can provide rapid confirmation
• Critical point: If diagnosis is highly suspected clinically and disease is extensive, you can start empiric treatment while awaiting culture results 3

2. First-Line Systemic Treatment

The choice depends on the causative organism (if known) or local epidemiology:

For Trichophyton species (most common in North America):

• Terbinafine 250 mg daily for 2-4 weeks (patient is >40 kg) 3, 2, 4
• Shorter treatment duration improves compliance
• Superior efficacy against Trichophyton species

For Microsporum species (if suspected or confirmed):

• Griseofulvin 1 g daily for 6-8 weeks (patient is >50 kg) 3
• More effective than terbinafine for Microsporum infections
• Take with fatty food to enhance absorption

If organism unknown and empiric treatment needed:

• Start with terbinafine given North American epidemiology favoring Trichophyton 4
• Switch based on culture results if needed

3. Adjunctive Topical Therapy

• Add antifungal shampoo (ketoconazole 2% or selenium sulfide 1%) to reduce spore transmission 3
• Avoid combination antifungal-corticosteroid creams (like clotrimazole/betamethasone) as these are associated with persistent and recurrent infections in children and adolescents 5, 6, 2

Critical Considerations for Recurrent Disease

Investigate Why Recurrence is Occurring:

1. Non-compliance with previous treatment regimens
2. Inadequate treatment duration or suboptimal dosing
3. Reinfection from family members, close contacts, or contaminated fomites
4. Organism resistance to previously used antifungals (emerging concern with terbinafine-resistant strains) 7
5. Immunocompromise (though patient described as healthy)

Additional Measures for Recurrent Cases:

• Screen and treat family members and close contacts, especially for anthropophilic species like T. tonsurans 3
• Disinfect personal items: hairbrushes, combs, hats with bleach or 2% sodium hypochlorite solution 3
• Continue treatment until mycological cure is achieved, not just clinical improvement 3
• Obtain repeat fungal cultures to confirm clearance 3

If Treatment Fails

Second-Line Options:

• Itraconazole 100 mg daily for 4 weeks (or 5 mg/kg/day for 2-4 weeks) 3

  • Effective against both Trichophyton and Microsporum species
  • Licensed for use in patients >12 years old 3

• If terbinafine was used first-line for suspected Trichophyton but failed, switch to griseofulvin

• If griseofulvin was used first-line for Microsporum but failed, continue for additional 2-4 weeks if showing clinical improvement 3

For Refractory Cases:

• Consider fluconazole or voriconazole in exceptional circumstances 3
• Obtain antifungal susceptibility testing if available, particularly given emerging resistance patterns 7

Common Pitfalls to Avoid

1. Using topical therapy alone for extensive or recurrent disease—this will fail 3, 1
2. Prescribing antifungal-steroid combinations—these mask symptoms, allow infection to persist, and are associated with recurrence 5, 6
3. Stopping treatment when lesions look better clinically—must achieve mycological cure to prevent relapse 3
4. Failing to address household contacts—leads to reinfection cycles 3
5. Not obtaining fungal culture—prevents species-directed therapy and identification of resistant organisms 2, 7

Monitoring and Follow-Up

• Repeat mycological sampling until clearance is confirmed 3
• Follow-up at 2-4 weeks to assess clinical response
• If no improvement by 4 weeks, reassess compliance, consider resistance, and switch to second-line therapy 3
• Patient can attend school during treatment 3

The emergence of antifungal-resistant dermatophytes, particularly terbinafine-resistant T. indotineae, is an increasing concern 7, making culture confirmation and susceptibility testing increasingly important in refractory cases.